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Comprehensive epigenetic landscape of
rheumatoid arthritis fibroblast-like synoviocytes
Rizi Ai1, Teresina Laragione2, Deepa Hammaker3, David L. Boyle3, Andre Wildberg1, Keisuke Maeshima3,
Emanuele Palescandolo4, Vinod Krishna4, David Pocalyko4, John W. Whitaker4, Yuchen Bai4, Sunil Nagpal4,
Kurtis E. Bachman4, Richard I. Ainsworth1, Mengchi Wang1, Bo Ding1, Percio S. Gulko2, Wei Wang1,5 &
Gary S. Firestein3
Epigenetics contributes to the pathogenesis of immune-mediated diseases like rheumatoid
arthritis (RA). Here we show the first comprehensive epigenomic characterization of RA
fibroblast-like synoviocytes (FLS), including histone modifications (H3K27ac, H3K4me1,
H3K4me3, H3K36me3, H3K27me3, and H3K9me3), open chromatin, RNA expression and
whole-genome DNA methylation. To address complex multidimensional relationship and
reveal epigenetic regulation of RA, we perform integrative analyses using a novel unbiased
method to identify genomic regions with similar profiles. Epigenomically similar regions exist
in RA cells and are associated with active enhancers and promoters and specific transcription
factor binding motifs. Differentially marked genes are enriched for immunological and
unexpected pathways, with “Huntington’s Disease Signaling” identified as particularly pro-
minent. We validate the relevance of this pathway to RA by showing that Huntingtin-
interacting protein-1 regulates FLS invasion into matrix. This work establishes a high-
resolution epigenomic landscape of RA and demonstrates the potential for integrative ana-
lyses to identify unanticipated therapeutic targets.
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Rheumatoid arthritis (RA) is an aggressive immune-mediatedjoint disease with synovial inflammation and joint destruc-tion1. Despite improvements in therapy, many patients have
persistent inflammation and progressive disability. Epigenetic
alterations such as DNA methylation and histone modification
might contribute to RA pathogenesis and provide clues to identify
novel therapeutic targets2–7. Much of the effort to define the RA
epigenome has focused on fibroblast-like synoviocytes (FLS) of the
synovial intimal lining, which invade the cartilage and assume a
unique aggressive phenotype in patients with RA8.
Individual epigenetic marks, such as DNA methylation mea-
sured by arrays, have been investigated in RA, sometimes together
with gene expression or DNA polymorphisms9, 10. The previous
integrative analyses of these data were relatively simple, using
overlapping marks to identify multi-evidence genes, for example.
Despite insights gained from these analyses, a comprehensive and
global characterization of the epigenomic landscape is needed to
define its contribution to pathogenesis of RA. Furthermore,
although, multiple omics technologies could provide a unique
opportunity to define the global epigenomic landscape of RA,
they also pose a great challenge to analyze in one integrative
model. Segmentation methods, such as ChromHMM11 and Seg-
way12 can identify functional elements but focus on histone
modifications and have not incorporated other data such as DNA
methylation. Furthermore, the epigenomic signals in RA and OA
FLS mostly differ in magnitude rather than lead to distinct epi-
genetic states, which also limits the applicability of segmentation
methods in which signals are discretized and the subtle amplitude
difference diminishes. Therefore, a systematic approach is needed
to integrate large-scale autoimmune disease epigenomes to define
the epigenomic landscape.
In this study, we apply multiple omics technologies on primary
cells from the site of disease in RA and control (osteoarthritis
[OA]) FLS, including (1) chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-seq) to map six histone
modifications, (2) assay for transposase accessible chromatin with
high-throughput sequencing (ATAC-seq) for mapping chromatin
accessibility genome-widely, (3) RNA sequencing (RNA-seq) to
measure whole genome RNA expression, and (4) whole-genome
bisulfite sequencing (WGBS) for DNA methylation level quantifi-
cation. To map the epigenomic landscape in RA, we integrate
diverse epigenomic data into a single analysis using our unbiased
method called EpiSig (http://github.com/Wang-lab-UCSD/EpiSig,
see Supplementary Methods). This platform clusters regions with
similar epigenomic profiles across all the RA and OA FLS samples.
The epigenomic co-modifications identify clustered regions that
share common functionality. As a result, this is the first time that
histone modifications, WGBS, ATAC-seq and RNA-seq data have
been combined into a single analysis to capture the deep com-
plexity of the epigenomic landscape in any immune-mediated
disease. Our approach incorporates signal intensities across all
samples and can capture subtle epigenetic differences that distin-
guish RA. EpiSig clusters enriched with differentially modified
epigenetic regions (DMER) were then extracted to identify RA-
specific pathways and transcription factor motifs that could be
mined for novel therapeutic targets. In addition to pathways known
to be relevant to RA, unexpected ones also emerged. Of particular
interest, the “Huntington’s Disease Signaling” pathway was dis-
covered as highly significant and biologically validated. The new
methodology and dataset provide a new way to identify RA-specific
targets that can be used to develop novel therapeutic agents.
Results
Epigenomic landscape of RA and OA FLS. A total of 191
genome-wide datasets were generated across 11 RA and 11 OA
samples, including 130 histone modification datasets, 22 open
chromatin datasets, 20 RNA-seq datasets and 19 DNA methy-
lation datasets. Six histone modifications marks were analyzed,
including histone H3 lysine 4 trimethylation (H3K4me3),
associated with promoter regions; H3 lysine 4 monomethylation
(H3K4me1), associated with enhancer regions; H3 lysine 27
acetylation (H3K27ac), associated with increased activation of
promoter and enhancer regions; H3 lysine 36 trimethylation
(H3K36me3), associated with transcribed regions; H3 lysine 27
trimethylation (H3K27me3), associated with Polycomb repres-
sion; and H3 lysine 9 trimethylation (H3K9me3), associated
with heterochromatin regions. Additional epigenomic marks
include: open chromatin regions, profiled by ATAC-seq,
denoting regions of accessible chromatin, and typically asso-
ciated with regulator binding; DNA methylation, commonly
associated with repressed regulatory regions, profiled with
WGBS; and RNA-seq used for measuring gene expression levels
(Fig. 1a). We integrated nine datasets and provided global views
of the first high-resolution functional epigenomic landscape of
RA and OA FLS (Fig. 1b).
Identification of epigenomically co-modified regions. For
integrative analysis of these diverse epigenomic data, EpiSig was
used to find regions sharing similar epigenomic profiles across all
the samples (Fig. 1c). The method first divided the whole genome
into 5 kb regions and identified regions with any enriched epi-
genomic signals. We then iteratively identified clusters: in each
iteration, regions that shared the most similar signal patterns
were determined as a seed and the remaining regions in this
cluster were assigned or rejected using a Gibbs sampling alike
method. In each step, the 5 kb regions were shifted and oriented
to align the patterns correctly. This is the first time WGBS,
ATAC-seq and RNA-seq data have been integrated with histone
marks to capture the greater complexity. The software is available
at http://wanglab.ucsd.edu/star/EpiSig and http://github.com/
Wang-lab-UCSD/EpiSig, and is further described in Supple-
mentary Methods).
EpiSig identified 169,502 signal-enriched 5 kb regions that were
grouped into 125 epigenomic clusters. Each cluster contains an
average of 1356 regions that share similar epigenomic profiles
across all FLS lines (Fig. 2a and Supplementary Fig. 1). We then
grouped similar epigenomic patterns (Fig. 2a). All the samples
were sequenced together, so there was no batch effect that could
contribute to these observations. To facilitate interpretation of the
results, individual clusters were further combined into nine
groups, which we call “sections”, using a self-organizing map
algorithm (SOM).
Overall, the 9 sections show distinct epigenomically co-
modified functional characteristics. Examples of these signal
profiles in the epigenomic landscape are shown in Fig. 2a. Of the
epigenomically defined sections, section I is highly enriched in
H3K27ac, H3K4me3 and open chromatin regions with relatively
weaker H3K4me1, which has high coverage in the TSS, 1 kb
upstream of the TSS and 5′-UTR regions. CpG islands are also
highly covered in this section, but most are de-methylated,
indicating active promoter regions. Section II is enriched in
H3K27ac, H3K4me1 signals and open chromatin regions, and
low in DNA methylation, which is likely associated with active
enhancer regions. This section is highly enriched with intergenic
regions. Section III is largely composed of bivalent promoters,
characterized by intermediate H3K4me3 signals together with
the repressive mark H3K27me3, and enriched with regions
around annotated TSSs. Notably, the poised promoters are highly
enriched with chromosome X loci (~21% of regions in section III
are located on chromosome X).
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Section IV includes signals of H3K27ac and H3K4me1,
together with strong signals of H3K36me3 and RNA-seq. In
addition, this section covers low-intergenic regions and is likely
associated with intragenic enhancers. Both section V and VII
represent actively transcribed regions as indicated by strong
H3K36me3 and RNA-seq signals, albeit relatively weaker in
section V compared to section VII and with locations highly
biased toward the gene body. Section VI and IX represent
repressive regions marked by strong signal of H3K27me3.
Compared with section VI, section IX shows a strong signal for
heterochromatin mark H3K9me3 but much lower signals of open
chromatin or DNA methylation. The coverage of intergenic
region is high in these two sections. Lastly, H3K9me3 is enriched
in section VIII together with high H3K36me3 signal, suggesting
that these regions are associated with heterochromatin or zinc
finger protein genes13. Interestingly, the genomic location of this
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Fig. 1 Overview of RA integrative analysis pipeline. a Schematic representation of major omics methods used in RA FLS. b Epigenomic landscape of RA FLS
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section is largely biased toward chromosome 19 (35%) and X
(35%) (Supplementary Fig. 2).
DMERs between RA and non-RA. After defining the overall
epigenomic landscape for FLS, we compared the relative intensity
of each epigenetic mark between RA and our non-RA control. A
total of 31,969 DMERs were identified across the 125 clusters
(Fig. 2b and Supplementary Data 1). Open chromatin regions
were found in most regions, with 9813 DMERs between RA and
OA. A total of 339 differentially expressed genes (DEGs, >2-fold
change and Benjamini-Hochberg [B-H] adjusted p-value <0.05)
were also identified between RA and OA (Supplementary
Table 1). Of these, 124 and 215 were over-expressed or under-
expressed in RA relative to OA, respectively. For ChIP-seq
DMERs, H3K27ac predominated in 9804 DMERs, followed by
H3K4me1 and H3K4me3 with 4516 and 2867 DMERs, respec-
tively (Supplementary Fig. 3). Compared to narrow peaks
(H3K4me3, H3K4me1, and H3K27ac), histone marks with broad
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Fig. 2 Genome-wide multidimensional clusters in RA and non-RA genomes. a A total of 125 genome-wide 5 kb multidimensional clusters were grouped into
nine sections based epigenetic marks. From left to right of the upper panel shows the aligned 125 clusters, each of which includes 11 RA and 11 OA FLS lines:
(1) the organization of clusters into epigenetically defined sections (see text); (2) genome annotation heatmap with coverage of each cluster, with
22 separate FLS lines shown within each cluster; (3) 125 cluster IDs; (4) the number of 5 kb regions in each epigenetic cluster (log10 scale); (5) the
characteristics of each region within the clusters, such as the relative abundance of transcription start sites (TSS), gene bodies, or introns; (6) chromosome
location of each region within the clusters (box shows high occupancy at chromosome 19); (7) differences in signals of epigenetic marks between RA and
OA; and (8) percentage of DMERs each cluster. In the middle panel, boxplot examples of clusters in different sections corresponding to LBH regions in the
genome browser (bottom panel) demonstrating differences between RA and OA and how the FLS marks can be categorized as sections I, II, IV, and VII14. b
DMERs with enhancer and promoter histone marks account for the most common differences between RA and OA. The red and yellow lines connect
H3K27ac and H3K4me3 bars to the genome browser, which shows an example of how those marks are differentially modified between RA and OA
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peaks (H3K27me3, H3K9me3, and H3K36me3) tended to have
less peak abundance. In addition, 3175 DNA methylation DMERs
were identified. Examples of H3K27ac and H3K4me3 DMERs are
shown in the genome browser screenshot in Fig. 2a. The pairwise
correlations between DMERs (histone modifications, open chro-
matin and DNA methylation) and gene expression are shown in
Supplementary Fig. 4. Low correlations were observed for pair-
wise correlations, while the three-dimensional plots showed
higher correlation among H3K4me1/3, RNA-seq and H3K27ac.
To find the co-localization of DMERs and RA-associated genetic
variations, 378 unique SNPs in 524 RA associations were
downloaded from GWAS Catalog, 10 unique SNPs were over-
lapped with DMERs identified in our study (Supplementary
Table 2). Interestingly, the co-localization was found in LBH14, 15,
which was identified by our previous DNA methylation studies
and plays a critical role in cell proliferation. It also provides
further evidence that our unbiased methods have biologic rele-
vance. The SNP associated with gene FADS1, FADS2, and FADS3
overlapped with three DMERs (H3K27ac, H3K27me3, and
H3K4me3).
Integrative analysis reveals novel biological pathways. To reveal
the top enriched differentially modified biological pathways in
RA, we used a stringent cutoff for DMERs (q-value <0.01) and
selected 13 clusters with significant DMER enrichment for
functional pathway analysis (Fig. 3a and Supplementary Table 3).
Of these, nine clusters that associate with active enhancer regions
had predominant differences in the number of H3K27ac DMERs
(44.3% of the DMERs) that distinguish RA from OA (see Fig. 3a
for the specific clusters). Moderate differences between RA and
OA were also observed in open chromatin (21.1% of the DMERs).
8.4% of the differences between RA and OA in these clusters were
due to the H3K4me1. The other four clusters had characteristics
of active promoter regions, with large differences between RA and
OA observed in mark H3K4me3 (47.4%) and intermediate dif-
ferences in H3K27ac (25.1%). H3K4me1 DMERs account for
2.7% of all DMERs between RA and OA in these clusters. Thus,
the key differences that distinguish the RA epigenomic landscape
related to transcriptional regulatory regions like enhancers and
promoters. The size, percentage and significance of enriched
DMERs are shown in Fig. 3a.
Statistically significant differentially modified pathways (B-H
adjusted p-value from Fisher’s exact test <0.05) involving the
genes in the clusters with DMERs were found in 8 of the 13
clusters (Supplementary Table 4). Multiple enriched pathways in
each individual cluster involved inflammation, immune response,
matrix regulation, and cell migration, which supports the
different known disease mechanisms of RA. Equally striking,
however, was the number of biological pathways that could not be
predicted based on the literature or current understanding of RA
(see below). Cluster 8, with 579 DMERs, showed the highest
DMER enrichment (Fig. 3a). Cluster 8 is associated with active
enhancer regions, and 52% of the DMER differences between RA
and OA are due to the H3K27ac mark. DMERs in open
chromatin regions and DEGs are 16% and 10% of the DMERs,
respectively. The cluster with the next most significantly enriched
DMERs is cluster 1, which is associated with active promoter
regions. About 74% of difference between RA and OA in cluster 1
is due to promoter mark H3K4me3. The activation mark
H3K27ac accounted for ~11% of DMERs. Cluster 7 is the third
most DMER enriched cluster and with a 59% difference between
RA and OA for H3K27ac.
Interestingly, RA-specific pathways “Role of Osteoblasts,
Osteoclasts and Chondrocytes in Rheumatoid Arthritis” and
“Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritis” were significant and only enriched in
clusters associated with active enhancer regions. Pathways
enriched in clusters associated with active promoter regions are
more generally associated with regulatory function. For instance,
clusters 7 and 8, associated with active enhancers, are especially
important as “RA-specific” clusters and have the two enriched
RA-associated pathways (Fig. 3b and Supplementary Table 4).
Therefore, these active enhancer associated regions are a
characteristic chromatin state that distinguishes RA and OA.
Other notable pathways that have been observed in our
previous integrative analysis5, 16 using less robust methodology
and different technology (e.g., methylation chips) include
“Integrin Signaling”, “Leukocyte Extravasation Signaling”, and
“p53 Signaling”. The current dataset confirm those findings,
validating the current methodology. As noted, many additional
non-obvious pathways also emerge from the epigenomic land-
scape and could be used to identify potential pathogenic genes.
To select biological pathways for subsequent target identifica-
tion, pathways were also prioritized based on their frequency in
the 8 clusters with significantly enriched pathways, and top 28
most frequently enriched ones that appeared in two or more
clusters are shown in Fig. 4a. Among the most significant
pathways, we found that “Phospholipase C Signaling”, “p53
Signaling”, “Integrin Signaling”, and “Protein Kinase A signaling”
were particularly notable. Of interest, the one that appeared the
most often was totally unexpected, namely “Huntington’s Disease
Signaling”. This pathway is enriched in four different clusters
with 45 differentially modified genes (DMGs) associated (Fig. 4a)
(see below for biologic validation).
Cluster-specific transcription factor motif discovery. Motif
analysis in DMERs regions was then performed on the 13 clusters
with significantly enriched DMERs in order to understand the
drivers of pathogenic pathways. Known motifs and de novo
motifs that appeared in two or more clusters are listed in Fig. 4b.
The top abundant known motifs are from bZIP and Runt
families, binding to promoter regions to control gene expression.
For example, TF AP-1 in bZIP family, containing c-Jun and c-
Fos, regulates gene expressions of inflammatory cytokines,
growth factors, and matrix-degrading matrix metalloproteinases
(MMPs), and is crucial to joint destruction in RA17. The Runt
family potentially plays a role in development of autoimmunity in
RA. Interestingly, multiple transcription factors from Stat family
are enriched in cluster 7 (Supplementary Table 5). One of these,
STAT3, is a key pathway for IL-6 signal transduction, and IL-6
blockade is a highly effective therapy for RA and acts by blocking
synovial STAT3 phosphorylation18.
Biological validation of differentially modified pathways. To
determine the functional relevance of non-obvious pathways, we
focused on the “Huntington’s Disease Signaling” pathway because
it was the most commonly enriched pathway and was not known
to be associated with immune-mediated disease (Fig. 4a and
Supplementary Fig. 5). There are a multitude of genes in this
pathway that could serve as potential targets in this pathway, and
we noted that on Huntingtin-interacting protein-1 (HIP1)
appears in many key locations. The protein participates in
clathrin-mediated endocytosis and cell signaling. It also regulates
cell invasion in oncology19, 20 but its potential role has not been
explored in inflammatory diseases.
Initial studies showed that HIP1 protein is constitutively
expressed in FLS and can be depleted in cells with siRNA (Fig. 5a
and Supplementary Fig. 6). We then examined the effect of
control and HIP1-deficient FLS in an in vitro invasion model, a
model that correlates with in vivo cartilage and joint damage21, 22.
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04310-9 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1921 | DOI: 10.1038/s41467-018-04310-9 |www.nature.com/naturecommunications 5
N
um
be
r o
f D
M
ER
0
200
400
600
H3K27ac
H3K4me1
H3K4me3
H3K36me3
H3K27me3
H3K9me3
Open chrom
RNA-seq
DNA methyl
24347 21332394 35 1818
Clus
ter
DM
ER 
enr
ichm
ent
3
40
–
lo
g(q
 
va
lu
e)
a
b
II
Sec
tion I
24
34
7 2
13
32
39
4
35
18
1
8DM
ER 
com
pos
ition
Cl
us
te
r 1
DMGs
FXN, TJP2
ARHGAP26
ATP6AP1L, FRMD4B, LMOD3, TMEM167A
SKAP2, SNX10
TBX15, WARS2
ARHGEF3
GALNT18, PTPN20A, ST6GAL1, SYT15, UBE2E2
SEPT11, SHROOM3
ALDH8A1, ANKRD46, ARHGEF28, BEGAIN, C15orf27, C1orf115,
C1QTNF9, C7orf10, CDH1, CITED4, DNAJC15, ENC1, ENOX1, ETFA, 
FAM124B, FOXD1, HABP2, KLF9, LY86, MAL2, MARC2, MARCH10, 
MRC2, NOV, NR3C1, PDIA5, QKI, RASGRP1, RNF19A, RPS6KC1, 
RREB1, SGK1, SMAD2, SNCAIP, SNX2, SPATA13, TANGO6, TCF7L2, 
THBS1, TMEM174, TRPM3, VASH2, WARS, ZBTB7C
DYNAP
FAM210A, GYPA, HHIP, LDLRAD4
BBC3, CHRNA2, CLIP2, DDIT4, EDN2, HIVEP3, IRF2BPL, KCTD15, 
KLHDC4, KY, LSM14A, OSBPL6, PRR24, PTK2B, RFC2, RHOD, SLC7A5, 
TSPAN15
MLPH, PICALM, SYTL2
CADM1
CBLN1, CORO2B, ITGA11, KLF2, ZNF423
EPAS1
LCTL, SMAD6
FSTL4, HSPA4
RTN4R, ZDHHC8
AKT3, ATP10A, GABRB3, ZBTB18
SNX10
PTPRD
FGF1, SPRY4
ADCY8, AKAP6, AMOTL1, ASAP1, ATP2B1, CADPS, CAV3, CDH20, 
CHIC2, CLIC5, CTAGE1, DYNLRB2, ELOVL2, F3, FEZF2, FGFR1, 
GADL1, GATA6, GKN1, HCK, IRF2BP2, LNX1, LYPLAL1, MAF, MAP4K4,
MARCKS, MCTP2, MDM1, NARS2, NPAS3, PAG1, PIWIL4, RBBP8, 
RGMA, RNF152, SLC44A3, SLIT2, ST3GAL1, STC1, STT3B, SUPT3H, 
SYCP2L, TACC1, TCF4, TENM4, TM9SF4, TMEM132C, TMEM75, 
TOMM20, TXNL1, ZFAT, ZNF704
ESM1, GZMK, SKAP2
CD180, CYB5B, PIK3R1
EBAG9, LMX1B, NA, SPTBN1, SYBU, TSPYL6
FBXO7, TIMP3
C10orf105, SLC29A3
ALDH1L2, MRPL44, SERPINE2, SLC7A1, TAMM41, TBL1XR1, VGLL4
SARS
TBX19
CAPN9, CDHR3, EFCAB10, IARS
BCR
AFAP1, CAPG, DESI1, FAM170A, LPAR1, MUSK, SLC16A3, XRCC6
DOK1, LOXL3
AGPAT4
PPP3CC
ATP10A, UBE3A
C1orf198, WARS
ACTN1, SFT2D2, ZFP36L1
ERRFI1
MAP3K4
Diff. modified marks 
(> 3)
H
3K
27
ac
H
3K
4m
e1
H
3K
4m
e3
H
3K
36
m
e3
H
3K
27
m
e3
H
3K
9m
e3
O
pe
n 
ch
ro
m
R
N
A-
se
q
D
N
A 
m
et
hy
l
DMGs
DMGs
Diff. modified marks 
(> 3)
Diff. modified marks 
(> 3)
Protein kinase A signaling 2.66 0.08
Phospholipase C signaling 2.66 0.09
p53 signaling 2.62 0.13
Retinoic acid mediated apoptosis signaling 1.96 0.16
Apoptosis signaling 1.96 0.13
RhoA signaling 1.96 0.11
RhoGDI signaling 1.96 0.09
Hypoxia signaling in the cardiovascular system 1.96 0.14
CCR3 signaling in eosinophils 1.95 0.10
Androgen signaling 1.95 0.11
Sumoylation pathway 1.95 0.12
Unfolded protein response 1.95 0.15
fMLP signaling in neutrophils 1.71 0.10
nNOS signaling in neurons 1.67 0.15
Calcium-induced T lymphocyte apoptosis 1.67 0.13
Death receptor signaling 1.67 0.11
Nitric oxide signaling in the cardiovascular system 1.67 0.10
Adipogenesis pathway 1.48 0.09
Nur77 signaling in T lymphocytes 1.46 0.13
VEGF signaling 1.46 0.10
Pancreatic adenocarcinoma signaling 1.46 0.09
UVA-induced MAPK signaling 1.46 0.10
Regulation of cellular mechanics by calpain protease 1.41 0.13
Huntington's disease signaling 1.38 0.07
Breast cancer regulation by stathmin1 1.31 0.07
Top 25 biological pathways
Human embryonic stem cell pluripotency 5.22 0.15
Axonal guidance signaling 3.84 0.08
Role of osteoblasts, osteoclasts and chondrocytes 
in rheumatoid arthritis
3.24 0.10
Ovarian cancer signaling 3.03 0.12
Protein kinase A signaling 2.42 0.08
Wnt/β -catenin signaling 2.42 0.10
G-protein coupled receptor signaling 2.42 0.09
Urate biosynthesis/inosine 5'-phosphate degradation 2.42 0.36
CDK5 signaling 2.19 0.12
Gap junction signaling 2.06 0.10
Regulation of the epithelial-mesenchymal transition pathway 1.99 0.09
Ephrin receptor signaling 1.97 0.09
Purine nucleotides degradation II (aerobic) 1.97 0.26
Glioblastoma multiforme signaling 1.97 0.09
Epithelial adherens junction signaling 1.97 0.10
p53 signaling 1.97 0.11
Macropinocytosis signaling 1.97 0.12
Clathrin-mediated endocytosis signaling 1.97 0.09
FAK Signaling 1.92 0.11
Basal cell carcinoma signaling 1.92 0.13
Myc mediated apoptosis signaling 1.89 0.13
Role of macrophages, fibroblasts and endothelial cells 
in rheumatoid arthritis
1.89 0.07
Guanosine nucleotides degradation III 1.89 0.31
Leukocyte extravasation signaling 1.89 0.08
Virus entry via endocytic pathways 1.89 0.11
Top 25 biological pathways
Axonal guidance signaling 3.18 0.09
Amyotrophic lateral sclerosis signaling 3.18 0.15
Thyroid cancer signaling 2.85 0.23
Leukocyte extravasation signaling 2.55 0.10
Protein kinase A signaling 2.55 0.08
RhoA signaling 2.55 0.13
Hepatic fibrosis / hepatic stellate cell activation 2.53 0.11
Dopamine-DARPP32 feedback in cAMP signaling 2.33 0.11
Clathrin-mediated endocytosis signaling 2.18 0.10
Role of macrophages, fibroblasts and endothelial cells
in rheumatoid arthritis
2.17 0.08
Pregnenolone biosynthesis 1.90 0.40
Cholecystokinin/Gastrin-mediated signaling 1.88 0.12
Synaptic long term potentiation 1.87 0.11
Phospholipase C signaling 1.81 0.09
Regulation of the epithelial-mesenchymal transition pathway 1.74 0.09
Molecular mechanisms of cancer 1.74 0.07
Role of NFAT in cardiac hypertrophy 1.74 0.09
Role of osteoblasts, osteoclasts and chondrocytes 
in rheumatoid arthritis
1.71 0.08
Signaling by Rho family GTPases 1.71 0.08
Basal cell carcinoma signaling 1.71 0.13
Histidine degradation VI 1.71 0.31
Wnt/Ca+ pathway 1.71 0.14
Chondroitin sulfate biosynthesis (late stages) 1.64 0.16
Adipogenesis pathway 1.64 0.10
Factors promoting cardiogenesis in vertebrates 1.54 0.11
Top 25 biological pathways
–log(B-H
p value) Ratio
–log(B-H
p value) Ratio
–log(B-H
p value) Ratio
Cl
us
te
r 7
Cl
us
te
r 8
Fig. 3 Integrative analysis identified 13 clusters with significantly enriched DMERs. a The 13 enriched clusters are shown with the number of DMERs in each
cluster. Below, the relative abundance of various types of differential marks is shown and demonstrates the high abundance of active enhancer and active
promoter marks (section I and II). Nine clusters are associated with active enhancers and four with active promoters. b Characterization of three clusters
with the most DMERs (1, 7, and 8). Top DMGs (left) and top enriched biological pathways associated with these genes (right) are shown
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HIP1 deficiency unexpectedly decreased RA FLS invasion by
nearly 50% (n= 7 separate FLS lines, p-value <0.001 (paired t-
test), Fig. 5b). Morphology of HIP1-deficient RA FLS was then
evaluated by confocal microscopy (Fig. 5c, d). HIP1 was depleted
using siRNA, which decreased expression of the 116 kDa band on
western blot but not other control proteins. HIP1-deficient cells
lost their fusiform morphology and assumed a ‘stellate-like’
shape. Actin fibers became less organized and lamellipodia-like
structures did not form or were present in a non-polarized
manner without phospho-FAK co-localization. This phenotype is
commonly observed in cells that cannot migrate or invade and
suggests that HIP1 plays a role in FLS-induced invasion into
cartilage in RA23.
Discussion
Although treatment of RA has improved dramatically in recent
years, current targeted therapies usually fail to induce remission
and many patients do not respond to any available agent. Most
efforts to develop new therapies rely on candidate gene
approaches that have emerged from traditional biological
research that dissect pathogenesis. This approach has limited
potential to discover entirely new and unanticipated pathogenic
processes that contribute to disease. To address this need, we
developed genome-wide unbiased methodology and datasets that
can identify surprising pathways and genes involved in immune
dysfunction. By integrating multiple epigenetic technologies we
hoped to define pathogenesis of disease and discover non-obvious
targets.
The present studies focused on RA FLS which, unlike OA or
normal synoviocytes, display an imprinted aggressive phenotype
and invade cartilage explants when implanted in immunodefi-
cient mice24. RA FLS can grow under anchorage-independent
conditions, are less susceptible to contact inhibition, and are
resistant to apoptosis25, 26. They are more invasive in vitro and
produce cytokines and MMPs that serve as amplifying disease
mechanisms27. Imprinted RA FLS can also migrate from joint to
joint, potentially serving as a vector to disseminate the disease28.
While the adaptive immune system clearly contributes to RA17,
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innate immune functions regulated by FLS also participate29 but
have not been successfully targeted in humans.
We generated the largest collection of epigenomes for RA FLS
by profiling six histone modification patterns, open chromatin
regions, RNA expression and whole-genome DNA methylation
and established the first high-resolution global epigenomic
landscape for RA. To address the complex multidimensional
relationships of those epigenomes and identify co-modified
regions, integrative analysis was performed using a novel
unbiased method, EpiSig. The analysis grouped the RA genome
into 125 clusters based on epigenetic marks in multiple reg-
ulatory/functional elements. This is the first time whole-genome
DNA methylation, chromatin accessibility, and the transcriptome
have been incorporated into the integration method with histone
modifications which allows a detailed understanding of the epi-
genomic landscape.
Our systematic integrative analysis identified 13 of the 125
clusters with statistically significant DMER enrichment for
pathway analysis, which allowed us to prioritize biological path-
ways featured in promoter and enhancer regulatory modules. A
variety of pathways were found, some of which were expected
because they are related to immune responses or matrix regula-
tion or were previously identified by our previous limited ana-
lyses. However other pathways were totally unexpected, such as
“Huntington’s Disease Signaling” and a variety of others that still
need to be explored. In the “Huntington’s Disease Signaling”
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pathway, many genes that could serve as potential targets. Pre-
vious studies found HIP1 is associated with cell movement in
cancer19, 20. However, HIP1 is particularly prominent in this
pathway and its potential involvement in oncology led us to
reason that this might be especially interesting and worth
exploring further. The fact that we were able to validate the role of
a key protein in the “Huntington’s Disease Signaling” pathway
indicates that our unbiased method can identify novel potential
therapeutic targets. Other genes that are differentially marked in
this pathway include phosphatidylinositide 3-kinases, activator
protein-2, histone deacetylases, and heat shock protein-70. We
are particularly intrigued by the potential use of histone deace-
tylase inhibitors to remodel the epigenome and alter enhancer
activity, thereby modifying aggressive RA FLS behavior. In
addition, transcription factor motifs were identified that distin-
guish RA from OA and the bZip motifs were particularly noted as
enriched in DMERs. These motifs play a critical role in the reg-
ulation of metalloproteinases and cytokines that are pathogenic in
RA.
Because, we have previously evaluated joint location-specific
changes in RA16, we also assessed the differences between hip and
knee FLS lines (n= 5 and 3, respectively for WGBS data).
However, the present study was underpowered due to limited
sample size and identified <200 DMERs using the same criteria.
The previous studies showed that the magnitude of the differ-
ences between joints within RA is much less than the difference
between OA and RA. Thus it is not surprising that many more
samples are required to evaluate more subtle joint location-
specific marks, and it is unlikely that these modest differences
affect the overall RA vs. OA analysis.
The use of FLS permitted evaluation of a homogeneous cell
population of primary cells from the site of disease and avoided
the confounding problem of deconvoluting lineage-specific marks
in mixed cell populations. The comparators for this analysis were
OA FLS, which are derived at the time of joint replacement and
are a commonly used comparator for RA because matched nor-
mal synovial cells are not readily available. We have previously
shown that analysis of OA FLS DNA methylation patterns do not
identify any systematic differences compared to normal that
would affect the present study4. The use of cultured cells rather
than freshly isolated cells could potentially influence the results,
but we have previously shown that the DNA methylation sig-
nature is remarkably stable in RA FLS for many months in cul-
ture and they retain the aggressive phenotype4. Despite these
potential limitations, the present studies provide a full dataset
required for detailed analysis of primary cells isolated directly
from the site of this destructive disease.
Our methodology focused on RA, but it is disease agnostic and
can be applied to any immune-mediated disease if the datasets are
available. The use of FLS simplified our studies because they are a
homogenous cell lineage and play a critical role in rheumatoid
joint damage. Studies on peripheral blood cells or other cells in
disease tissue would require separation into individual lineages
because single cell assays are not feasible with current technology
for most of the marks studied. Future studies are required to
validate the large number of unanticipated targets and pathways
as well as explore diversity between patients and individualize
treatment.
Methods
Human FLS. This study was approved by the Institutional Review Board of Uni-
versity of California, San Diego, and informed consent was obtained from all
participants. Synovial tissue was obtained from patients with RA and OA at the
time of total joint replacement or synovectomy. The diagnosis of RA conformed to
American College of Rheumatology 1987 or 2010 criteria30, 31, and the diagnosis of
OA conformed to American College of Rheumatology 1986 or 1991 criteria32, 33.
The mean ages of RA and OA patients were 55 ± 9 and 66 ± 12, respectively. Joint
locations were available for 10 RA patients (6 knee, 3 hip, 1 hand) and 11 OA (8
knee, 3 hip). Of the 7 RA patients with clinical information available, treatment
included NSAIDs (n= 5), low dose prednisone (<5 mg/d) (n= 4), methotrexate (n
= 4), methotrexate plus leflunomide (n= 1), TNF blocker (n= 3), IL-6 blocker (n
= 1). Biologics, methotrexate and leflunomide were generally discontinued 4 weeks
before surgery. Serology was available for 3 RA patients. One patient was RF
positive and 2 patients were CCP and RF negative. Therapy information was
available for 5 OA patients, who were treated with NSAIDs (n= 2) or analgesics.
Enzymatic disaggregation of synovium was performed as previously described14.
Cells were allowed to adhere overnight and non-adherent cells were removed.
Adherent FLS were split at 1:3 when 70–80% confluent and used from passages 4
through 7, when they are a homogeneous population of fibroblasts. Primary FLS
were cultured (at 5% CO2, 37 °C) in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with L-glutamine, gentamicin, penicillin/streptomycin, and 10%
heat-inactivated fetal bovine serum (FBS) as previously described34. For synchro-
nization experiments, cells were serum starved for 2 days and transfected with
siRNA in DMEM containing 1% FBS and supplements, followed by addition of
10% FBS.
RNA-seq data processing. Total RNA was extracted and the quality of all samples
was evaluated using an Agilent Bioanalyzer. The samples had an average RNA
Integrity Number (RIN) of 9.4 with a minimum of 7.5. Sequencing libraries were
prepared using TruSeq Stranded Total RNA RiboZero protocol from Illumina.
Libraries were pooled and sequenced with an Illumina HiSeq 2000. Raw read
quality was evaluated using FastQC.
Adapter and low quality bases below a quality score of 15 were trimmed from
raw RNA-seq reads. After trimming, reads with less than 30 bp were further
discarded. The remaining reads were aligned to human reference genome hg19
using STAR (2.3.0) and assembled and quantified by HTSeq (0.5.4p5). DEGs were
identified using DESeq2 package in R. To be considered a DEG, twofold change of
gene expression levels between RA and OA should be achieved and the B-H
adjusted p-value is <0.05. For the following analysis, transcription levels were then
converted to log2 of the normalized counts.
ChIP-seq data processing. The sample preparation for ChIP-seq was performed
using the Zymo-spin ChIP kit (Zymo Research, Irvine, CA) according to the
manufacturer’s instructions. Raw ChIP-seq reads of 11 RA and 11 OA samples,
each with six histone modifications (H3K4me1, H3K4me3, H3K9me3, H3K27ac,
H3K27me3, and H3K36me3) and input data, were mapped to hg19 genome using
bwa (0.7.7-r441). Peaks were called using MACS2 (2.1.0.20150420.1) using a p-
value cutoff of 0.1 for broad marks (9me3, 27me3, 36me3) and 0.01 for narrow
marks (4me1, 4me3, 27ac). To assess the library complexity and the enrichment of
the data, quality control was done using several metrics, including non-redundant
fraction of reads, fraction of reads that fall into peak regions, PCR bottleneck
coefficient, normalized strand cross-correlation coefficient and the relative strand
cross-correlation coefficient. ChIP-seq DMERs were determined by DiffBind
package in R with q-value <0.05 for six marks.
ATAC-seq and WGBS data processing. ATAC-seq sample preparation was
followed by previous protocol35 and was sequenced by Epinomics (San Francisco,
CA). ATAC-seq data were processed using Bowtie and read depth was normalized.
ATAC-seq DMERs were determined by DiffBind package in R with q-value <0.05.
The bisulfite conversion and sequencing were performed by GATC Biotech AG
(Germany). WGBS data were processed with DSS package in R. Differentially
methylated loci (DMLs) were determined and Differentially methylated regions
were defined by callDMR function with delta beta of DMLs >0.05 and q-value
<0.0015.
Genome-wide multidimensional clustering by EpiSig. EpiSig is derived from
the previously published method ChromaSig36 with greatly improved performance
and capability in capturing sequencing profile patterns among large number of
datasets. Compared to previous ChromaSig developed in Perl script, EpiSig was
rewritten with C++ in a single standalone program and provides two running
modes, which significantly improved speed and performance. Regarding to
searching accuracy, EpiSig is an unsupervised learning approach to simultaneously
clusters, aligns sequencing patterns without prior knowledge. Before the pattern
alignment, one important step is to find the initial seeds among the remained loci.
EpiSig provides another information entropy based method to find the candidate
seed loci. First, the maximum intra-entropy loci (enriched signal window) are
selected, then the minimum inter-entropy loci are added to the seed set. Actually
they measure the similarities among them. To handle the different sequencing
types such as histone modification data, RNA-Seq data and other data types, EpiSig
utilizes a bi-clustering thinking to concatenate different data types into one larger
data window when aligning them. This provides a more meaningful and accurate
pattern discovering approach.
To assess the co-modified regions in RA and non-RA, all sequencing datasets
were processed, normalized and filtered ensuring a uniform description of the
information based on read depth. For final data processing, inputs were subtracted
from the histone mark data. The comprehensive dataset is then preprocessed by
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EpiSig by dividing the data into binned binary files. After this, EpiSig performs data
normalization using a sigmoid function, followed by scanning the data for enriched
regions. To facilitate interpretation of the result, these individual EpiSig clusters
were further combined into sections using a SOM algorithm.
Genome and chromosome annotation of targeted regions. The human genome
hg19 was used as reference genome with functional annotation in GENCODE v19.
CpG islands and TSSs were downloaded from UCSC table browser. The genome
annotation was performed by overlapping targeted regions with gene exon, intron,
intergenic region, 3′- and 5′-UTR, TSS, 1 kb upstream of TSS, and CpG island. The
coverage is defined as the percentage of overlapped regions. The chromosome
annotation was calculated as the percentage of 5 kb regions in each chromosome
and followed by chromosome length and cluster size normalization.
Pairwise correlations of DMERs and gene expressions. To plot correlations
between DMERs and gene expressions, DMERs (from six histone modifications,
open chromatin regions, and DNA methylation) were assigned to nearby genes
using GREAT analysis with default settings37. If multiple DMERs were assigned to
the same gene, the average of fold changes was calculated. Log2 fold change was
used for the plot except for WGBS.
Pathway prioritizing. To prioritize enriched pathways, stringent cutoff of q-value
<0.01 was applied to DMERs from six histone modification marks and open
chromatin region. Because different analysis methods were used for identifying
DEG and DNA methylation DMERs, no additional filter was applied. Enriched
DMERs (from six histone modifications, open chromatin regions and DNA
methylation) were assigned to nearby genes using GREAT analysis with default
settings. The DMER assigned genes together with DEGs were collected for pathway
analysis in each cluster. However, we did not assign different weights to DEGs/
DMERs. To test for significant enrichment of DMER in each cluster, hypergeo-
metric test was performed using R package. For prioritizing pathways, clusters with
hypergeometric test q-value <0.05 and number of associated genes >200 were
selected. Ingenuity pathway analysis (IPA) (QIAGEN Redwood City) was used for
pathway analysis. Finally, pathways were prioritized based on their frequency in the
enriched clusters.
Motif discovery. Motif analysis was performed in 13 clusters using HOMER38.
Due to small input regions, q-value of 0.1 was used as the cutoff of known motif
enrichment. de novo motif was also discovered and scores were calculated indi-
cating matches to known motifs. de novo motifs with p-value <1e−12 and score
>0.7 were listed.
siRNA knockdown of HIP1. Dharmacon SMARTpool siRNA targeting HIP1,
GAPDH, and a non-coding control were purchased from Thermo Scientific
(Lafayette, CO) and transfected into RA FLS according to the manufacturer’s
instructions. Briefly, FLS derived from RA FLS were transfected siRNA in the
presence of DharmaFECT reagent 1 in DMEM media with NEAA. Two days later,
cells were used for invasion experiments or immunofluorescence. Aliquots were
used for cell lysis to confirm gene knockdown with western blot and qPCR.
FLS invasion assay. Invasion was assayed in a transwell system using Matrigel-
coated inserts (BD Biosciences, Franklin Lakes, NJ), as previously described39, 40.
FLS in serum free medium were placed in the upper compartment of the Matrigel-
coated inserts. The lower compartment was filled with 10% FBS and incubated for
24 h. The insert was stained with crystal violet and the total number of cells that
invaded through Matrigel was counted with ImageJ cell counter software.
Western blot analysis. A quantity of 5 μg of FLS protein/lane were loaded into a
NuPAGE 10% Bis-Tris gel (Invitrogen) in the presence of MES buffer (Invitrogen)
and electrophoresed under reducing conditions. After transfer, the membranes
were incubated with anti-HIP1 rabbit monoclonal antibody (Abcam, Cambridge,
MA). HRP-conjugated anti-rabbit IgG antibody (GE Healthcare, Pittsburgh, PA)
was used as secondary antibody. Proteins were visualized with Clarity Western ECL
substrate (Bio-Rad, Hercules, CA). Rat anti-actin antibody (Cell Signaling tech-
nology, Danvers, MA) was used as loading control.
HIP1 gene expression. qPCR was performed as previously described41. Ct
(threshold cycle) values were adjusted for Ubiquitin in each sample (ΔCt), and fold
differences were calculated with the 2−ΔΔCt method.
Confocal immunofluorescence microscopy. RA FLS were cultured on coverslips
to 20–30% confluence, transfected for 6 h with HIP1 or control siRNA, serum
starved overnight and then treated for 5, 15, 30 min with complete media with 10%
FBS. Cells were then fixed with 4% formaldehyde for 15 min and permeabilized
with PBS/Triton X-100, 0.1% for 5 min. Non-specific binding was blocked with 5%
nonfat milk. A rabbit anti-phospho-FAK (Y397) (Abcam) was used as primary
antibody, and a Alexa Fluor 488 (green) donkey anti-rabbit IgG (Invitrogen) used
as secondary antibody. Alexa Fluor 350 (blue) Phalloidin (Invitrogen) was used to
stain the actin filament. A Leica DMi8 fluorescent microscope system was used for
visualization with the appropriate filters, with Leica Lax X software. Cell cytoske-
leton was scored as previously described39 using a ×600 magnification.
Data availability. The data that support the findings of this study have been
deposited in Gene Expression Omnibus with the primary accession code
GSE112658. Other data that support the findings of this study are available from
the corresponding authors upon request.
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